Circio Holding ASA (CRNA) 5

[hgsd300]

ESGCTs offisielle regler sier at posterabstractene kan omtales offentlig fra kl. 08.00 på konferansens første dag, mens abstractet til den muntlige presentasjonen er under embargo frem til kl. 08.00 på selve presentasjonsdagen.

[Multiple]

Så kan det nevnes at Circio tidligere har publisert/børsmeldt poster og “slides” samtidig, i forbindelse med den muntlige presentasjonen, som denne gangen finner sted onsdag kl 10.
Det kan hende de gjør det på samme måte nå, selv om kongressembargo varer til hhv. kl 08 i dag og i morgen.

[Pk2k]

https://www.esgctcongress.com/embargo-policy?

An embargo on public communication of abstracts remains in place until the day of the scheduled presentation.

Nye embargo regler så vi får nok ikke pressemelding før imorgen

[Samen]

Spennende dag. De har jo sagt at det skal komme nye data, men om dette uteblir - ups

[Crna]

Blir i følge Ceo ikkje før presentasjonen starter,det vil vel sei kl 10

[chris3]

ikke sagt noe om nye data.

[Fartin]

Blir vel mest spennende i morgen med oral pres.

[Baerntis]

Den er i dag kl 10.00

[dri]

Sånne presentasjoner planlegges månedsvis i forveien. Blir overraska hvis det kommer nye data i dag.

Edit: overraska

[TekBot]

Circio delivers three presentations at ESGCT and shows novel AAV circVec 5.2 design for enhanced heart expression and specificity

• New heart-optimized circVec 5.2 design shows approximately 200-fold higher
  gene expression compared to conventional AAV vectors, with 95% cardiac
  specificity and less than 1% off-target expression in liver
  …

Vis børsmeldingen

• The competitive oral presentation at ESGCT follows the ASCGT presentation in
  May, marking back-to-back selections at the two leading global gene and cell
  therapy conferences
• In the oral presentation, Circio is showcasing the versatile circVec
  circular RNA gene expression platform, with a focus on non-viral vectors for
  in vivo cell therapy applications
• Two posters demonstrate the potential of circVec to enhance gene expression
  and specificity across heart, eye and CNS, supporting the development of
  more effective and safer gene therapies

Oslo, Norway, 28 October 2026 – Circio Holding ASA (OSE: CRNA), a
biotechnology company developing novel circular RNA expression technology for
gene and cell therapy, today announces the materials for its oral and two
poster presentations that are being delivered at the 33rd Annual Congress of
the European Society of Gene and Cell Therapy (ESGCT) in Hamburg, Germany.

In the oral presentation, Circio s CTO Dr. Thomas B Hansen presents the latest
developments for its circVec platform and its potential for in vivo CAR-T
therapy, an area attracting significant momentum in the life sciences
industry. Circio s approach formulates circVec DNA constructs into LNP
particles with the aim to establish a novel technology platform for potent,
durable and immune-quiet CAR expression in T-cells. This unique combination
could establish a new in vivo therapeutic window for cancer and autoimmunity,
bridging the gap between transient, short-lived RNA-based approaches and
permanently integrating, irreversible lentiviral systems.

“Presenting the evolution of the circVec technology from the first to the
fifth generation in an oral session at ESGCT is an excellent opportunity to
show how far the platform has come and its range of therapeutic applications,”
said Dr. Thomas B Hansen, CTO of Circio. “Across heart, eye and CNS, circVec
delivers strong, specific and consistent expression gains over conventional
AAV gene therapy, driven by the superior stability of circular RNA. The broad
and robust performance makes circVec a platform technology that can be applied
across different vectors, tissues and diseases. With each new generation we
have further improved both potency and precision, and we see substantial
potential for circVec as an integral component of next generation gene and
cell therapies.”

The two posters highlight the potential of circVec to improve the potency and
specificity of AAV vectors to support the development of more effective next
generation gene therapies. circVec 3.2 and 4.0 show up to approximately 40-,
50- and 60-fold increased expression in heart, eye and CNS, respectively. The
new heart-optimised AAV9 circVec 5.2 design further enhances potency and
cardiac specificity, achieving approximately 200-fold higher gene expression
than conventional mRNA-based AAV9. Importantly, circVec 5.2 shows 95%
heart-specific expression, compared with 25% for conventional mRNA-based AAV9,
while reducing off-target liver expression to less than 1%, compared with 9%
for conventional AAV9. These results highlight the ability of circVec to
enhance on-target tissue activity while minimizing unwanted payload expression
in off-target tissues, an important feature for enabling more specific gene
therapies and reducing toxicity.

“Being selected for a competitive oral presentation at both the ASGCT and
ESGCT 2026 annual meetings reflects the growing recognition of Circio in the
gene and cell therapy field,” said Dr. Erik D Wiklund, CEO of Circio.
“Following the new and enhanced circVec 5.2 design and validation in vivo,
Circio is advancing its pre-clinical cardiac program. This is an area where
circVec really stands out, with strong potential to offer enhanced and safer
gene therapies for patients with high and urgent medical needs. With the USD
88 million in new funding secured during 2026, Circio is now rapidly
progressing into in vivo heart disease models to confirm the potential of
AAV-circVec in therapeutic systems. Studies are starting in first quarter
2027, and we can look forward to several important read-outs during the year.”

Circio presentations at ESGCT Annual Congress 2026:

circVec: A DNA Vector Platform Harnessing Intracellular Circular RNA
Biogenesis for Next-Generation T Cell Therapies
Dr. Thomas B Hansen, oral presentation
Session: Non-viral vectors/nanotechnology and RNA therapeutics I
10:00am Wednesday 28 October 2026

circVec Reduces AAV Vector Dose Through Durable and Potent Circular RNA
Expression
O Leary et al., poster presentation
Poster Session I: AAVs/non integrative vectors
Wednesday 28 October 2026

AAV-circVec Enhances Cardiac Expression While Minimizing Dose and Cellular
Stress
Hansen et al., poster presentation
Poster Session II: Cardiovascular & Muscular Diseases
Thursday 29 October 2026

The materials are attached to this press release and are made available on the
Circio website.

Circio plans to host an R&D webcast at the end of November to discuss the
ESGCT data in more detail and present results from ongoing in vivo studies in
heart and eye that are expected to complete during November.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Neil Hunter – Hunter PR
Phone: +44 782 125 5568
Email: neiljameshunter@gmail.com

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA
expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression
technology for next generation RNA, DNA and viral therapeutics. The
proprietary circVec platform is based on a modular genetic construct designed
for efficient biogenesis of multifunctional circRNA inside target cells. The
circVec platform has applications in multiple therapeutic settings, including
genetic medicine, cell therapy and chronic disease. It has demonstrated
75-fold increased RNA half-life and up to 60-fold enhanced protein expression
vs. conventional mRNA-based viral and non-viral vector systems, with the
potential to become a new gold-standard gene expression technology. The
circVec R&D activities are being conducted by the wholly owned subsidiary
Circio AB in Stockholm, Sweden.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation (MAR) and is subject to the disclosure requirements
pursuant to MAR and section 5-12 of the Norwegian Securities Trading Act. The
information was submitted for publication at 2026-10-28 10:00 CET.

This stock exchange announcement was published by Mats Hermansen, VP Finance,
on behalf of the Company, at the time and date stated above in this
announcement.

Kilde

[tverilytt]

circVec 5.2 faktisk, de har kalt den bare 5 tidligere?

[Bob_le_Plast]

Hehe, vi ser en klassisk sell on news i dag.
Det som aldri slutter å overraske meg er alle dimlingene som forventer ett-eller-annet helt absurd kursdrivende basert på presentasjoner på en vitenskapelig kongress.

Men hvis vi skal røre litt grøten, så viser meldingen over at på AAV akkumulerer Circio nå data som viser at de totalt utklasser konvensjonell AAV når det gjelder hjerte:

• Circvec AAV med 95% organ spesifikt uttrykk vs 25% std AAV
• 200X høyere proteinuttrykk vs std AAV
• 1% off-target uttrykk i lever vs 9% med std AAV

Circio utklasser, på dette stadiet, fullstendig tradisjonell AAV - behandling. Og tradisjonell AAV er forlengst etablert som godkjent behandling…

[Samen]

Nei, men er det som forventes tydeligvis. Var en snev ironi i det jeg skrev

Traff bra også. Markedet reagerer som forventet også.

[hgsd300]

2026-esgct-circio-talk-261028.pdf

[Crna]

kjøre på:)

We’re hiring
Scientists at all levels
Early-career Experienced Senior

[gatfre]

Hvis 200x er protein uttrykk, er hoppet fra circVec 3.2 (~40x protein) til 5.2 omtrent femdobbelt på ett generasjonsskifte. Sterkt, og det styrker caset betydelig.

[Kennyxr]

Men… hva er det en event betalende sam partner ser i disse tallene, som vi ikke ser, ettersom dette lar vente på seg, å andre blir kjøpt opp preklinisk å med tilsv dårligere data? Det bør jo dukke opp noe iløpet av rel kort tid, ellera begynner ting å renne ut i sand, eller?

[MrKirie]

Vet ikke om jeg ville sagt det renner ut i sanden akkurat. Jeg tenker vi får mye spennende fremover med BP samarbeid, car-t og ind i hjerte (ev andre) fremover. Oppkjøp er vel kanskje mest realistiske ved NHP data.

[Bob_le_Plast]

Ift betalende samarbeidspartnere er det ingenting som renner ut i sanden slik jeg ser det.

Circio melder selv at resultatene er bedre enn forventet og jeg vil tippe det går raskere nå siden selskapet er opp-kapitalisert med flere folk på lab og nytt utstyr som kan gi enda bedre data.

Akkurat det prosjektet med topp 5 BP i CNS er det de forteller minst om, så her kan alt skje på kort varsel.
Det siste er selvsagt mitt eget euforiske bull-scenario og bør ikke vektlegges noe. Helst bør dere glemme det umiddelbart

[tverilytt]

Håper de er smarte og dytter mest mylig kostnader inn i BP prosjektet, både utstyr og man hours